Frederic Garban

Prof. Frederic Garban

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
SVSandrine Venier
Sandrine Venier
NVNathan Vaxelaire
Nathan Vaxelaire
PJPeggy Jacon
Peggy Jacon
ACAdrien Carabelli
Adrien Carabelli
ADAntoine Desbiolles
Antoine Desbiolles
PDPascal Defaye
Pascal Defaye
Pulsed field ablation (PFA) has been proposed as a novel alternative to radiofrequency (RF) and cryoablation in the treatment of atrial fibrillation (AF). Following the occurrence of two cases of acute kidney injury (AKI) secondary to haemolysis after a PFA procedure, we evaluated haemolysis in a cohort of consecutive patients. Two cases of AKI occurred in last May and June 2023. AKI was secondary to acute and severe haemolysis after a PFA procedure. From June 2023, a total of 68 consecutive patients (64.3 ± 10.5 years) undergoing AF ablation with PFA were enrolled in the study. All patients had a blood sample the day after the procedure for the assessment of haemolysis indicators. The pentaspline PFA catheter was used with a total number of median applications of 64 (54; 76). Nineteen patients (28%) showed significantly depleted haptoglobin levels (<0.04 g/L). A significant inverse correlation was found between the plasma level of haptoglobin and the total number of applications. Two groups were compared: the haemolysis+ group (haptoglobin < 0.04 g/L) vs. the haemolysis− group. The total number of applications was significantly higher in the haemolysis+ group vs the haemolysis - group respectively 75 (62; 127) vs 62 (54; 71) P = 0.011. More than 70 applications seem to have better sensitivity and specificity to predict haemolysis. Intravascular haemolysis can occur after certain procedures of PFA. Acute kidney injury is a phenomenon that appears to be very rare after a PFA procedure. However, caution must be exercised in the number of applications to avoid severe haemolysis.

1 April 2018 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
FGFrederic Garban
Frederic Garban
AGAudrey Guyard
Audrey Guyard
HLHelene Labussière
Helene Labussière
CBClaude-Eric Bulabois
Claude-Eric Bulabois
TMTony Marchand
Tony Marchand
FGfor the Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group
for the Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) Study Group
Platelet transfusion to prevent or treat bleeding due to thrombocytopenia is standard therapy worldwide.1 In recent years, the risk of transfusion-transmitted infections (TTIs) has been greatly reduced.2 However, infectious agent transmission—in particular, bacteria—remains a significant risk associated with platelet transfusion.3-5 One solution to further reduce the risk of TTIs is photochemical pathogen reduction (PR),6 a process by which pathogens are significantly depleted in number,7 albeit with some exceptions.8,9 However, PR technologies, such as amotosalen–UV-A treatment, induce functional platelet alterations.10,11 Previous clinical studies12,13 have raised concerns about the clinical effectiveness of pathogen-reduced platelets compared with standard untreated platelets. A 2013 Cochrane meta-analysis14 of published clinical trials reported a nonstatistically significant relative risk of 1.06 (95% CI, 0.93-1.21; P = .39) with regard to grade 2 or higher bleeding associated with pathogen-reduced platelets and concluded that not enough evidence was available to be sure that such platelets work as effectively as standard platelets to prevent bleeding. A recently updated analysis15 reported a 1.10 (95% CI, 0.97-1.25; P = .15) relative risk of grade 2 or higher bleeding associated with pathogen-reduced platelets.

9 July 2024 in Anaesthesia Critical Care & Pain Medicine
Verified
Journal Article
Closed access
ATAlexandre Theissen
Alexandre Theissen
GFGilles Folléa
Gilles Folléa
FGFrederic Garban
Frederic Garban
MCMonique Carlier
Monique Carlier
SPSilvia Pontone
Silvia Pontone
Emmanuel RineauEmmanuel Rineau
Emmanuel Rineau

1 September 2014 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
MMMathieu Meunier
Mathieu Meunier
CBClaude Eric Bulabois
Claude Eric Bulabois
ATAnne Thiebaut-Bertrand
Anne Thiebaut-Bertrand
RIRaphael Itzykson
Raphael Itzykson
MCMartin Carre
Martin Carre
JCJean Yves Cahn
Jean Yves Cahn
Acute graft-versus-host disease (aGVHD) still remains the main cause of morbidity and mortality after allogeneic stem cell transplantation. Moreover, patients who did not respond to first-line treatment with glucocorticosteroids have a very poor outcome. Some studies suggested that alemtuzumab (a humanized monoclonal antibody against the CD52 antigen) might be effective for treatment of refractory aGVHD. Here we report a single-center experience with alemtuzumab in refractory gastrointestinal aGVHD. From September 2009 to April 2012 at the Grenoble medical university center, 24 patients who had presented a refractory gastrointestinal aGVHD to corticosteroid, or after another immunosuppressive drug, were retrospectively analyzed. Most patients (n = 19) presented stage 4 gastrointestinal aGVHD. Response to treatment (either complete or partial) was observed in 15 patients (62.4%). The overall survival rate at 1 year for all patients was 33.3% (95% confidence interval [CI], 15.9% to 51.9%) and for responders, 53.3% (95% CI, 26.3% to 74.4%). Two patients died from infection, 5 patients from recurrent GVHD, and 1 from an uncontrolled post-transplant lymphoproliferative disorder.

1 November 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
LBLionel Berthoin
Lionel Berthoin
BTbertrand toussaint
bertrand toussaint
FGFrederic Garban
Frederic Garban
AGaudrey LE GOUELLEC
audrey LE GOUELLEC
BCBenjamin Caulier
Benjamin Caulier
DLDavid Laurin
David Laurin

29 October 2019 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
CDClémence Deteix
Clémence Deteix
O(On Behalf Of The Société Francophone de Greffe de Moelle Et de Thérapie Cellulaire (Sfgm-Tc)
On Behalf Of The Société Francophone de Greffe de Moelle Et de Thérapie Cellulaire (Sfgm-Tc)
FMFlorence Mesnil
Florence Mesnil
SFSabine Furst
Sabine Furst
NMNoel Milpied
Noel Milpied
FGFrederic Garban
Frederic Garban